# Aurobindo Pharma (AUROPHARMA) — Stock analysis

> Faxioms all-in-one stock review. Canonical page: https://faxioms.com/stocks/auropharma

## Current market snapshot

- Exchange: NSE
- Country: India
- Price: ₹1,800
- Change: +0.84%
- As of: 2026-11-06
- 1D return: +0.84%
- 5D return: +7.05%
- 1M return: +9.42%
- Latest complete quarter: fy27_q2

## Faxioms Analysis

_As of 2026-11-06_

### Technical Outlook

AUROPHARMA is trading at ₹1785.0, near its 252-day high (+98.3% position in range), with a bullish structure confirmed across daily, weekly, and monthly timeframes. Price remains above all key moving averages (EMA/SMA 20/50/200) and the Supertrend indicator. On November 5, 2026, the stock posted an extreme upward volume anomaly (+4.7% return, 3.51x volume ratio), coinciding with an active monthly Morning Star pattern. While the monthly trend is established (ADX 30.2), the daily trend is still developing (ADX 20.6), suggesting momentum is building but not yet fully entrenched on the shorter horizon. Risk metrics show annualized volatility of +28.4% and a maximum drawdown of -24.5%. Immediate support lies at ₹1756.33 (-1.61%), with further levels at ₹1740.47 and ₹1722.73.

- Trend Structure: Bullish across all horizons; price trades above EMA/SMA 20/50/200 and Supertrend on daily, weekly, and monthly charts.
- Momentum & Participation: Extreme daily volume surge (+3.51x ratio) on Nov 5 accompanied a +4.7% price gain; monthly ADX (30.2) indicates established trend vs. daily ADX (20.6) which is developing.
- Range Position: Trading near 252-day highs (+98.3%); current drawdown is 0.0%, but historical max drawdown stands at -24.5%.
- Key Levels: Support at ₹1756.33 (-1.61%), ₹1740.47 (-2.49%), and ₹1722.73 (-3.49%). A break below ₹1756.33 would test deeper support zones.

- Morning Star
- Hammer
- Outside Bar
- Doji
- Harami
- Bullish Engulfing Reversal
- Inside Bar

### News Context

Aurobindo Pharma reported consolidated net profit of ₹1,124 crore for the quarter ended September, marking a 32.5% year-on-year increase driven by record revenue of ₹10,263 crore, up 24%. This growth was supported by strong performance in key international markets, with U.S. and European revenues rising 25% and 27% respectively. The company also declared an interim dividend of ₹7 per share. In broader market context, Aurobindo Pharma was among several stocks in focus as Indian equity benchmarks extended their winning streak to a fifth consecutive session, with the Nifty 50 closing at 23,961 on broad-based buying. Additionally, Axis Securities included Aurobindo Pharma in its list of top technical picks for the year ahead, assigning buy ratings with specific target prices, citing positive momentum structures.

- Q2 FY27 net profit rose 32.5% YoY to ₹1,124 crore, with revenue hitting a record high of ₹10,263 crore (up 24%).
- U.S. and European revenues grew 25% and 27% respectively, contributing to the overall financial outperformance.
- The board declared an interim dividend of ₹7 per share alongside the Q2 results.
- Axis Securities assigned a buy rating with specific target prices, identifying positive momentum structures in its Diwali picks analysis.

- [Aurobindo Pharma Q2 net up 32.5% to ₹1,124 cr on higher revenue](https://www.thehindu.com/business/Industry/aurobindo-pharma-q2-net-up-325-to-1124-cr-on-higher-revenue/article71666685.ece)
- [Stocks in news: BSE, Lenskart, Nykaa, Bharti Airtel, LIC, Aurobindo Pharma and Nalco](https://economictimes.indiatimes.com/markets/stocks/news/stocks-in-news-bse-lenskart-nykaa-bharti-airtel-lic-aurobindo-pharma-and-nalco/articleshow/135548122.cms)
- [Aurobindo Pharma Q2: Net profit rises 32.5% to Rs 1,124 crore, revenue hits record high](https://www.moneycontrol.com/news/business/earnings/aurobindo-pharma-q2-net-profit-rises-32-5-to-rs-1-124-crore-revenue-hits-record-high-14070340.html)
- [Diwali picks: HAL, Kotak Bank, TechM, Sona BLW, Auro Pharma among top picks for upto 50% upside](https://www.businesstoday.in/markets/stocks/story/diwali-picks-hal-kotak-bank-techm-sona-blw-auro-pharma-among-top-picks-for-upto-50-upside-565067-2026-11-02)
- [Cash rewards coming? PFC, CONCOR, RITES, to Sonata- These firms to announce dividend with Q2 results 2026 this week](https://www.livemint.com/market/stock-market-news/cash-rewards-coming-pfc-concor-rites-pfc-to-sonata-these-firms-to-announce-dividend-with-q2-results-2026-this-week-11793537407103.html)

### What Changed

Aurobindo Pharma has materially shifted its capital return profile and demonstrated robust operational growth for the quarter ended September 2026. The company declared an interim dividend of ₹7 per share, with a record date set for 11 November 2026, signaling a commitment to shareholder returns alongside its earnings expansion. Financially, consolidated net profit rose 32.5% year-on-year to ₹1,124 crore, driven by a record revenue increase of 24% to ₹10,263 crore. This top-line growth was supported by strong performance in key international markets, where U.S. and European revenues grew by 25% and 27% respectively. Market pricing reflects this momentum, with the stock trading at ₹1,785 as of 5 November 2026, up from ₹1,705 in the prior observation period.

- Dividend Declaration: Interim dividend of ₹7 per share announced; record date is 11-Nov-2026.
- Profit Growth: Consolidated net profit increased 32.5% YoY to ₹1,124 crore for Q2 (ended Sept).
- Revenue Expansion: Record revenue of ₹10,263 crore, up 24% YoY, fueled by 25% U.S. and 27% European growth.
- Price Action: Stock price rose to ₹1,785 on 05-Nov-2026 from ₹1,705 in the previous observation.

- [Aurobindo Pharma Q2 net up 32.5% to ₹1,124 cr on higher revenue](https://www.thehindu.com/business/Industry/aurobindo-pharma-q2-net-up-325-to-1124-cr-on-higher-revenue/article71666685.ece)
- [SERIES:EQ |PURPOSE:INTERIM DIVIDEND - RS 7 PER SHARE |FACE VALUE:1 |RECORD DATE:11-Nov-2026 |BOOK CLOSURE START DATE:- |BOOK CLOSURE END DATE:-](https://www.nseindia.com/companies-listing/corporate-filings-actions)
- [Aurobindo Pharma Limited has informed the Exchange about Copy of financial results published in newspapers. |SUBJECT: Copy of Newspaper Publication](https://nsearchives.nseindia.com/corporate/AUROPHARMA_06112026112647_LtrToSEsQ2UFRpublished06112026.pdf)

### Official Filings

Aurobindo Pharma Limited reported consolidated results for Q2 FY27 (quarter ended September 30, 2026), showing revenue from operations of ₹10,263 crore, up 23.9% year-over-year, and net profit of ₹1,124 crore, a 32.5% increase. EBITDA before forex and other income stood at ₹2,156 crore with a 21.0% margin. The Board approved an interim dividend of ₹7.00 per equity share, with a record date of November 11, 2026, and payment expected by November 20, 2026. Corporate governance updates include the re-appointment of Independent Director Mangalam Ramasubramanian Kumar for a second five-year term starting April 1, 2027, subject to member approval. Operational developments include final USFDA approvals for 12 products, successful completion of the Lannett acquisition, and internal restructuring involving the transfer of ownership of Auro Pharma LLC, Russia, to Auropharm Overseas Limited for approximately ₹29 crore.

- Q2 FY27 Financial Performance: Revenue grew 23.9% YoY to ₹10,263 crore; Net Profit increased 32.5% to ₹1,124 crore; EBITDA margin was 21.0%.
- Interim Dividend Declaration: Board approved ₹7.00 per share; Record Date is November 11, 2026; Payment scheduled on or before November 20, 2026.
- Regulatory & Operational Milestones: Final USFDA approvals secured for 12 products; Acquisition of Lannett completed successfully.
- Governance & Restructuring: Re-appointment of Independent Director Mangalam Ramasubramanian Kumar proposed for a second term from April 1, 2027; Internal transfer of Russian subsidiary ownership valued at ~₹29 crore.

- [SERIES:EQ |PURPOSE:INTERIM DIVIDEND - RS 7 PER SHARE |FACE VALUE:1 |RECORD DATE:11-Nov-2026 |BOOK CLOSURE START DATE:- |BOOK CLOSURE END DATE:-](https://www.nseindia.com/companies-listing/corporate-filings-actions)
- [Aurobindo Pharma Limited has informed the Exchange about Copy of financial results published in newspapers. |SUBJECT: Copy of Newspaper Publication](https://nsearchives.nseindia.com/corporate/AUROPHARMA_06112026112647_LtrToSEsQ2UFRpublished06112026.pdf)
- [Aurobindo Pharma Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026. |SUBJECT: Outcome of Board Meeting](https://nsearchives.nseindia.com/corporate/AUROPHARMA_04112026194825_LtrToSEsOutcomeOfBM04112026.pdf)
- [Aurobindo Pharma Limited has informed the Exchange regarding a press release dated November 04, 2026, titled "Press release on Q2 FY27 Financial Results.". |SUBJECT: Press Release](https://nsearchives.nseindia.com/corporate/AUROPHARMA_04112026200852_LtrToSEsPressRelease04112026.pdf)
- [Aurobindo Pharma Limited has informed the Exchange about Investor Presentation |SUBJECT: Investor Presentation](https://nsearchives.nseindia.com/corporate/AUROPHARMA_04112026201054_LtrToSEsInvestorPresentation04112026.pdf)
- [Aurobindo Pharma Limited has informed the Exchange that Record date for the purpose of Dividend is 11-Nov-2026. |SUBJECT: Record Date](https://nsearchives.nseindia.com/corporate/AUROPHARMA_04112026201247_LtrToSEsDividendUpdate04112026.pdf)
- [Aurobindo Pharma Limited has informed the Exchange about transfer ownership of Auro Pharma LLC, Russia, from Auro Active Pharma Private Limited to Auropharm Overseas Limited, wholly owned subsidiaries of the Company |SUBJECT: Acquisition](https://nsearchives.nseindia.com/corporate/AUROPHARMA_04112026203119_LtrToSEsOwnershipTransferRussia04112026.pdf)
- [Aurobindo Pharma Limited has informed the Exchange regarding Change in Director(s) of the company. |SUBJECT: Change in Director(s)](https://nsearchives.nseindia.com/corporate/AUROPHARMA_04112026204230_LtrToSEsReappointmentofMrKumar04112026.pdf)

### Fundamentals

Aurobindo Pharma demonstrates a strengthening operating trajectory in Q2 FY2026-27, with revenue rising to ₹10,263 crore and net profit increasing to ₹1,124 crore. This follows a strong historical trend of cash generation, where Cash from Operating Activity grew from ₹2,435 crore in Mar 2024 to ₹5,526 crore in Mar 2026, and CFO/EBITDA conversion improved to 107% in the same period. The balance sheet shows asset growth to ₹61,754 crore as of Sep 2026, supported by a rise in equity to ₹39,398 crore. While borrowings increased overall to ₹8,234 crore (₹7,252 crore current, ₹982 crore non-current), the company maintains significant cash reserves of ₹6,232 crore. Shareholding remains stable with promoters holding ~51.88%. A key monitoring point is the rising Cash Conversion Cycle (252 days in Mar 2026) driven by higher inventory days (326 days), which warrants attention alongside upcoming quarterly disclosures.

- Q2 FY2026-27 Revenue: ₹10,263 crore; Net Profit: ₹1,124 crore; EPS: ₹19.57 per share.
- Historical Cash Flow Strength: CFO rose to ₹5,526 crore (Mar 2026); CFO/EBITDA conversion reached 107%.
- Balance Sheet Growth: Total assets ₹61,754 crore (Sep 2026); Equity ₹39,398 crore; Cash ₹6,232 crore.
- Working Capital Watch: Cash Conversion Cycle expanded to 252 days (Mar 2026) due to Inventory Days rising to 326 days.

### Bull Case

Aurobindo Pharma demonstrates a robust operational turnaround in the quarter ended September, with consolidated net profit rising 32.5% year-on-year to ₹1,124 crore and revenue hitting a record high of ₹10,263 crore, up 24%. This growth was driven by strong performance in key international markets, where U.S. and European revenues increased by 25% and 27% respectively. The company also declared an interim dividend of ₹7 per share, signaling confidence in cash flows. Technically, the stock exhibits bullish momentum across daily, weekly, and monthly timeframes, supported by positive directional indicators (Plus DI significantly higher than Minus DI) and a bullish Supertrend. The stock has delivered substantial returns over longer horizons, including +55.3% over the past year and +49.6% year-to-date as of November 2026, suggesting sustained investor interest despite broader market volatility.

- Q2 FY27 net profit surged 32.5% YoY to ₹1,124 crore on record revenue of ₹10,263 crore (+24%), driven by 25% U.S. and 27% European revenue growth.
- Interim dividend of ₹7 per share declared, reflecting improved liquidity and shareholder return capacity.
- Technical structure is bullish across daily, weekly, and monthly charts, with Plus DI (31.2 daily, 22.95 monthly) well above Minus DI, indicating strong upward momentum.
- Stock has gained +55.3% over the last year and +49.6% YTD, outperforming broader market trends with a current price of ₹1,785.

- [Aurobindo Pharma Q2 net up 32.5% to ₹1,124 cr on higher revenue](https://www.thehindu.com/business/Industry/aurobindo-pharma-q2-net-up-325-to-1124-cr-on-higher-revenue/article71666685.ece)
- [Stocks in news: BSE, Lenskart, Nykaa, Bharti Airtel, LIC, Aurobindo Pharma and Nalco](https://economictimes.indiatimes.com/markets/stocks/news/stocks-in-news-bse-lenskart-nykaa-bharti-airtel-lic-aurobindo-pharma-and-nalco/articleshow/135548122.cms)
- [Aurobindo Pharma Q2: Net profit rises 32.5% to Rs 1,124 crore, revenue hits record high](https://www.moneycontrol.com/news/business/earnings/aurobindo-pharma-q2-net-profit-rises-32-5-to-rs-1-124-crore-revenue-hits-record-high-14070340.html)
- [Diwali picks: HAL, Kotak Bank, TechM, Sona BLW, Auro Pharma among top picks for upto 50% upside](https://www.businesstoday.in/markets/stocks/story/diwali-picks-hal-kotak-bank-techm-sona-blw-auro-pharma-among-top-picks-for-upto-50-upside-565067-2026-11-02)
- [Cash rewards coming? PFC, CONCOR, RITES, to Sonata- These firms to announce dividend with Q2 results 2026 this week](https://www.livemint.com/market/stock-market-news/cash-rewards-coming-pfc-concor-rites-pfc-to-sonata-these-firms-to-announce-dividend-with-q2-results-2026-this-week-11793537407103.html)
- [SERIES:EQ |PURPOSE:INTERIM DIVIDEND - RS 7 PER SHARE |FACE VALUE:1 |RECORD DATE:11-Nov-2026 |BOOK CLOSURE START DATE:- |BOOK CLOSURE END DATE:-](https://www.nseindia.com/companies-listing/corporate-filings-actions)
- [Aurobindo Pharma Limited has informed the Exchange about Copy of financial results published in newspapers. |SUBJECT: Copy of Newspaper Publication](https://nsearchives.nseindia.com/corporate/AUROPHARMA_06112026112647_LtrToSEsQ2UFRpublished06112026.pdf)
- [Aurobindo Pharma Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026. |SUBJECT: Outcome of Board Meeting](https://nsearchives.nseindia.com/corporate/AUROPHARMA_04112026194825_LtrToSEsOutcomeOfBM04112026.pdf)
- [Aurobindo Pharma Limited has informed the Exchange regarding a press release dated November 04, 2026, titled "Press release on Q2 FY27 Financial Results.". |SUBJECT: Press Release](https://nsearchives.nseindia.com/corporate/AUROPHARMA_04112026200852_LtrToSEsPressRelease04112026.pdf)
- [Aurobindo Pharma Limited has informed the Exchange about Investor Presentation |SUBJECT: Investor Presentation](https://nsearchives.nseindia.com/corporate/AUROPHARMA_04112026201054_LtrToSEsInvestorPresentation04112026.pdf)

### FAQs

**What were Aurobindo Pharma's key financial results for Q2 FY27, and what dividend was declared?**

For the quarter ended September 30, 2026, Aurobindo Pharma reported a record revenue of ₹10,263 crore (up 24% year-on-year) and a net profit of ₹1,124 crore (up 32.5%). The Board also approved an interim dividend of ₹7 per share.

**When is the record date for the interim dividend, and what corporate actions accompanied the results?**

The record date for the ₹7 per share interim dividend is November 11, 2026. Alongside the financial results, the Board approved a merger scheme for wholly owned subsidiaries Auroactive Pharma Private Limited and Apitoria Pharma Private Limited with the NCLT, Hyderabad.

**How has the stock performed technically over the past year, and what are the current support levels?**

As of November 5, 2026, the stock closed at ₹1,785, reflecting a +55.3% return over the past year. Technical indicators show a bullish trend on daily, weekly, and monthly timeframes. Key support levels are identified at ₹1,756.33, ₹1,740.47, and ₹1,722.73.

- [Aurobindo Pharma Q2 net up 32.5% to ₹1,124 cr on higher revenue](https://www.thehindu.com/business/Industry/aurobindo-pharma-q2-net-up-325-to-1124-cr-on-higher-revenue/article71666685.ece)
- [Stocks in news: BSE, Lenskart, Nykaa, Bharti Airtel, LIC, Aurobindo Pharma and Nalco](https://economictimes.indiatimes.com/markets/stocks/news/stocks-in-news-bse-lenskart-nykaa-bharti-airtel-lic-aurobindo-pharma-and-nalco/articleshow/135548122.cms)
- [Aurobindo Pharma Q2: Net profit rises 32.5% to Rs 1,124 crore, revenue hits record high](https://www.moneycontrol.com/news/business/earnings/aurobindo-pharma-q2-net-profit-rises-32-5-to-rs-1-124-crore-revenue-hits-record-high-14070340.html)
- [Diwali picks: HAL, Kotak Bank, TechM, Sona BLW, Auro Pharma among top picks for upto 50% upside](https://www.businesstoday.in/markets/stocks/story/diwali-picks-hal-kotak-bank-techm-sona-blw-auro-pharma-among-top-picks-for-upto-50-upside-565067-2026-11-02)
- [Cash rewards coming? PFC, CONCOR, RITES, to Sonata- These firms to announce dividend with Q2 results 2026 this week](https://www.livemint.com/market/stock-market-news/cash-rewards-coming-pfc-concor-rites-pfc-to-sonata-these-firms-to-announce-dividend-with-q2-results-2026-this-week-11793537407103.html)
- [SERIES:EQ |PURPOSE:INTERIM DIVIDEND - RS 7 PER SHARE |FACE VALUE:1 |RECORD DATE:11-Nov-2026 |BOOK CLOSURE START DATE:- |BOOK CLOSURE END DATE:-](https://www.nseindia.com/companies-listing/corporate-filings-actions)
- [Aurobindo Pharma Limited has informed the Exchange about Copy of financial results published in newspapers. |SUBJECT: Copy of Newspaper Publication](https://nsearchives.nseindia.com/corporate/AUROPHARMA_06112026112647_LtrToSEsQ2UFRpublished06112026.pdf)
- [Aurobindo Pharma Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026. |SUBJECT: Outcome of Board Meeting](https://nsearchives.nseindia.com/corporate/AUROPHARMA_04112026194825_LtrToSEsOutcomeOfBM04112026.pdf)
- [Aurobindo Pharma Limited has informed the Exchange regarding a press release dated November 04, 2026, titled "Press release on Q2 FY27 Financial Results.". |SUBJECT: Press Release](https://nsearchives.nseindia.com/corporate/AUROPHARMA_04112026200852_LtrToSEsPressRelease04112026.pdf)
- [Aurobindo Pharma Limited has informed the Exchange about Investor Presentation |SUBJECT: Investor Presentation](https://nsearchives.nseindia.com/corporate/AUROPHARMA_04112026201054_LtrToSEsInvestorPresentation04112026.pdf)
## Technical analytics

- As of: 2026-11-06
- Daily trend: Weak Uptrend
- Weekly trend: Moderate Uptrend
- Pivot point: ₹1,759.27
- Risk regime: Price Risk Currently Contained

### Support levels
- 1401
- 1186.78125
- 1147.465625

### Resistance levels
- 1822.5333333333333
- 1860.0666666666666
- 1923.3333333333333

### Return and range metrics

| Metric | Value |
| --- | --- |
| return_1 | +0.84% |
| return_10 | +14.53% |
| return_1m | +6.33% |
| return_1y | +57.81% |
| return_20 | +9.42% |
| return_3m | +13.29% |
| return_5 | +7.05% |
| return_6m | +21.29% |
| return_since_start | +33.01% |
| return_ytd | +50.88% |

### Risk and volatility metrics

| Metric | Value |
| --- | --- |
| state | contained_risk |
| label | Price risk currently contained |
| summary | Recent drawdown and price variability remain within the producer's contained-risk thresholds. |
| maximum_drawdown | -24.46% |
| annualized_volatility | +28.33% |

## Quarterly financials

- Latest complete quarter: fy27_q2

# Aurobindo Pharma Limited Q2 FY2026-27: Revenue grows 24% year on year

Aurobindo Pharma’s revenue from operations rose 12.2% sequentially and 23.9% year on year to ₹10,263 crore in Q2 FY2026-27, the highest in the five-quarter series. Profit before tax increased 11.5% from Q1 to ₹1,691 crore, while profit for the period rose 8.9% to ₹1,124 crore and EPS reached ₹19.57. Operating cash flow was ₹3,283 crore, but investing outflows of ₹3,702 crore left quarterly free cash flow negative at ₹419 crore.

## Revenue and earnings growth

Revenue from operations increased by ₹1,113 crore from ₹9,150 crore in Q1 FY2026-27. It rose in each quarter of the five-quarter series, from ₹8,286 crore in Q2 FY2025-26. Total income, including ₹168 crore of other income, increased 10.8% sequentially to ₹10,432 crore.

Profit before tax was ₹1,691 crore, compared with ₹1,517 crore in Q1 FY2026-27 and ₹1,274 crore in Q2 FY2025-26. Profit for the period was ₹1,124 crore, up from ₹1,032 crore in the previous quarter and ₹848 crore a year earlier. Basic and diluted EPS were ₹19.57, up 9.6% sequentially and 33.9% year on year. Trailing 12-month EPS was ₹68.96.

## Costs and tax

Total expenses rose 11.2% sequentially to ₹8,741 crore, slightly below the 12.2% increase in revenue from operations. Other expenses increased 14.0% from Q1 FY2026-27 to ₹2,466 crore and were 23.8% higher than in Q2 FY2025-26. Employee benefit expense was ₹1,659 crore, cost of materials consumed was ₹2,980 crore, and depreciation and amortisation expense was ₹531 crore. Finance costs were ₹102 crore, broadly unchanged from the previous quarter.

Tax expense increased 16.7% sequentially to ₹564 crore. Current tax was ₹509 crore, down from ₹610 crore in Q1 FY2026-27, while deferred tax was a charge of ₹55 crore, compared with a credit of ₹127 crore in the prior quarter.

## Cash flow and investment

Operating cash flow was ₹3,283 crore; investing and financing activities used ₹3,702 crore and ₹596 crore, respectively. Free cash flow, calculated as operating cash flow plus investing cash flow, was negative ₹419 crore for the quarter.

At 30 September 2026, property, plant and equipment stood at ₹15,292 crore, compared with ₹14,330 crore at 31 March 2026. Capital work in progress was ₹3,487 crore, up from ₹3,009 crore; other intangible assets were ₹3,405 crore, up from ₹2,277 crore; and goodwill was ₹1,269 crore, compared with ₹800 crore.

## Balance sheet and working capital

Cash and cash equivalents were ₹6,232 crore at 30 September 2026, down from ₹7,191 crore at 31 March 2026 but above ₹5,402 crore at 30 September 2025. Other bank balances were ₹3,718 crore, up from ₹2,679 crore at 31 March 2026.

Inventories stood at ₹13,124 crore, compared with ₹12,053 crore at 31 March 2026 and ₹11,192 crore at 30 September 2025. Current trade receivables were ₹7,544 crore, up from ₹7,094 crore at 31 March 2026 and ₹5,891 crore at 30 September 2025.

## Key Takeaway

Q2 FY2026-27 delivered sequential and year-on-year growth in revenue, pre-tax profit and EPS, with revenue at its highest level in the five-quarter series. The quarter’s main counterpoint was negative free cash flow as investing outflows exceeded operating cash flow; property, plant and equipment, work in progress and intangible assets were also higher than at the previous fiscal year-end.

### Ratios

## Shareholding pattern

- Quarter: FY2027-Q2
- As of: 2026-09-30
- Promoter holding: +51.88%
- FII holding: +17.41%
- DII holding: +24.37%
- Mutual fund holding: +16.31%
- Retail holding: +4.69%
- Promoter pledged: +0.00%

### Major reported shareholders

- RPR SONS ADVISORS PRIVATE LIMITED, MRS.P.SUNEELA RANI (JOINTLY HOLDING) — +33.54% (Bodies Corporate)
- QUANT MUTUAL FUND - QUANT ARBITRAGE FUND — +4.91%
- KAMBAM NITHYANANDA REDDY — +4.37%
- SBI NIFTY MIDCAP 150 INDEX FUND — +3.51%
- KIRTHI REDDY KAMBAM — +3.46%
- HDFC MUTUAL FUND-HDFC ARBITRAGE FUND — +3.22%
- VENKATA RAMPRASAD REDDY PENAKA — +3.07%
- AXIS CLINICALS LIMITED, TRIDENT CHEMPHAR LIMITED, RPR SONS ADVISORS PVT.LTD. (JOINTLY HOLDING) — +2.86% (Bodies Corporate)
- LIFE INSURANCE CORPORATION OF INDIA — +2.85%
- NPS TRUST A/C - SBI PENSION FUND - UPS - CG  SCHEM — +2.80%

## Official filings

- 2026-11-06 — Corporate Action Notice: Aurobindo Pharma Limited - Ex-Date: 11-Nov-2026 — [Official attachment](https://www.nseindia.com/companies-listing/corporate-filings-actions)
- 2026-11-06 — Corporate Action Notice: Aurobindo Pharma Limited - Ex-Date: 11-Nov-2026 — [Official attachment](https://www.nseindia.com/companies-listing/corporate-filings-actions)
- 2026-11-06 — Generic Announcement: Aurobindo Pharma Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/AUROPHARMA_06112026112647_LtrToSEsQ2UFRpublished06112026.pdf)
- 2026-11-06 — Corporate Action Notice: Aurobindo Pharma Limited - Ex-Date: 11-Nov-2026 — [Official attachment](https://www.nseindia.com/companies-listing/corporate-filings-actions)
- 2026-11-04 — Generic Announcement: Aurobindo Pharma Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/AUROPHARMA_04112026194825_LtrToSEsOutcomeOfBM04112026.pdf)
- 2026-11-04 — Press Release: Aurobindo Pharma Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/AUROPHARMA_04112026200852_LtrToSEsPressRelease04112026.pdf)
- 2026-11-04 — Earnings Presentation: Aurobindo Pharma Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/AUROPHARMA_04112026201054_LtrToSEsInvestorPresentation04112026.pdf)
- 2026-11-04 — Generic Announcement: Aurobindo Pharma Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/AUROPHARMA_04112026201247_LtrToSEsDividendUpdate04112026.pdf)
- 2026-11-04 — Generic Announcement: Aurobindo Pharma Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/AUROPHARMA_04112026203119_LtrToSEsOwnershipTransferRussia04112026.pdf)
- 2026-11-04 — Generic Announcement: Aurobindo Pharma Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/AUROPHARMA_04112026204230_LtrToSEsReappointmentofMrKumar04112026.pdf)
- 2026-11-04 — Generic Announcement: Aurobindo Pharma Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/OUTCOME_934_WebXMLFile_20261104_220408260.xml)
- 2026-11-04 — Generic Announcement: Aurobindo Pharma Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/REG30_Restructuring_934_WebXMLFile_20261104_220622171.xml)
- 2026-11-04 — Generic Announcement: Aurobindo Pharma Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/REG30_Restructuring_934_WebXMLFile_20261104_220756048.xml)
- 2026-11-04 — Generic Announcement: Aurobindo Pharma Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/CIM_934_WebXMLFile_20261104_220944261.xml)
- 2026-11-04 — Financial Results Filing: Aurobindo Pharma Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/INTEGRATED_FILING_INDAS_1753285_04112026104508_WEB.xml)
- 2026-11-04 — Financial Results Filing: Aurobindo Pharma Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/INTEGRATED_FILING_INDAS_1753288_04112026104818_WEB.xml)
- 2026-10-26 — Board Meeting Notice: Aurobindo Pharma Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/AUROPHARMA_26102026073907_LtrToSEsIntimationofBM26102026.pdf)
- 2026-10-26 — Board Meeting Notice: Aurobindo Pharma Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/PRIOR_INTIMATION_934_WebXMLFile_20261026_075640876.xml)
- 2026-10-26 — Generic Announcement: Aurobindo Pharma Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/PRIOR_INTIMATION_934_WebXMLFile_20261026_075640876.xml)
- 2026-10-26 — Generic Announcement: Aurobindo Pharma Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/AUROPHARMA_26102026122238_LtrToSEsQ2202627EarningCallDate26102026.pdf)
- 2026-10-26 — Generic Announcement: Aurobindo Pharma Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/SAIIM_934_WebXMLFile_20261026_123343564.xml)
- 2026-10-14 — Shareholding Disclosure: Aurobindo Pharma Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/SHP_1737425_14102026114826_WEB.xml)
- 2026-10-09 — Generic Announcement: Aurobindo Pharma Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/AUROPHARMA_09102026113104_LtrToSEsNewsPaperPublicationSplWindow09102026.pdf)
- 2026-10-05 — Generic Announcement: Aurobindo Pharma Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/AUROPHARMA_05102026130726_LtrToSEsReg74Compliance30092026.pdf)
- 2026-10-03 — Press Release: Aurobindo Pharma Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/AUROPHARMA_03102026170252_LtrToSEsPressReleasePerampanelUSFDAapproval03102026.pdf)

## News and market events

- 2026-11-07 — Economic Times: **Samir Arora backed Helios Mid Cap Fund adds Aurobindo Pharma, 2 others, increase stake in Paytm, MCX and 16 others** — Samir Arora-backed Helios Mid Cap Fund added Aurobindo Pharma, Zetwerk, and PVR Inox to its portfolio in October while increasing stakes in Paytm, MCX, and 16 other stocks. The fund exited Park Medi World, expanded its holdings to 77 stocks across 23 sectors, and reported assets under management of Rs 2,421 crore as of October 31, 2026. — [Source](https://economictimes.indiatimes.com/mf/analysis/samir-arora-backed-helios-mid-cap-fund-adds-aurobindo-pharma-2-others-increase-stake-in-paytm-mcx-and-16-others/articleshow/135631989.cms)
- 2026-11-07 — Mint: **Diwali Muhurat trading stocks+ dividend: Expert picks 2 stocks for Samvat 2083 with record dates next week - Do you own?** — Ahead of the Diwali Muhurat trading session on November 8, 2026, Ravi Singh of Master Capital Services Ltd. recommends Aurobindo Pharma, Balkrishna Industries, and Mahindra & Mahindra for long-term investment based on their fundamental strength and potential upside over the next 12 months. The article highlights that Aurobindo Pharma and Balkrishna Industries have set November 11 as the record date for their respective equity dividends, adding a payout opportunity to the stock picks. — [Source](https://www.livemint.com/market/stock-market-news/diwali-muhurat-trading-stocks-dividend-expert-picks-2-stocks-for-samvat-2083-with-record-dates-next-week-do-you-own-11794039951310.html)
- 2026-11-06 — CNBC-TV18: **50+ stocks to trade ex-date next week: HUL, ONGC, Dabur among key names; dividends worth ₹315.21 per share** — More than 50 stocks and investment trusts are scheduled to trade ex-date next week for various corporate actions, including dividends, rights issues, and share buybacks. The combined value of the 51 announced dividend entries totals ₹315.21 per share, with Bayer CropScience declaring the highest individual payout at ₹90 per share. — [Source](https://www.cnbctv18.com/market/50-stocks-to-trade-ex-date-next-week-hul-ongc-dabur-among-key-names-dividends-worth-rs315-21-per-share-20029093.htm)
- 2026-11-05 — The Hindu: **Aurobindo Pharma Q2 net up 32.5% to ₹1,124 cr on higher revenue** — Aurobindo Pharma reported a 32.5% year-on-year increase in consolidated net profit to ₹1,124 crore for the quarter ended September, driven by a record 24% rise in revenue to ₹10,263 crore. The growth was attributed to strong performance across key markets, with U.S. and European revenues rising 25% and 27% respectively, alongside a declared interim dividend of ₹7 per share. — [Source](https://www.thehindu.com/business/Industry/aurobindo-pharma-q2-net-up-325-to-1124-cr-on-higher-revenue/article71666685.ece)
- 2026-11-05 — Economic Times: **Stocks in news: BSE, Lenskart, Nykaa, Bharti Airtel, LIC, Aurobindo Pharma and Nalco** — Indian equity benchmarks extended their winning streak to a fifth consecutive session, with the Nifty 50 closing at 23,961 amid broad-based buying and optimism for a breakout above 24,000. Several companies, including BSE, Lenskart, Nykaa, Bharti Airtel, LIC, Aurobindo Pharma, and NALCO, are in focus as investors track their September-quarter earnings, sales data, and operational updates. Experts advise monitoring support levels around 23,750–23,700 as the bullish trend persists. — [Source](https://economictimes.indiatimes.com/markets/stocks/news/stocks-in-news-bse-lenskart-nykaa-bharti-airtel-lic-aurobindo-pharma-and-nalco/articleshow/135548122.cms)
- 2026-11-04 — MONEYCONTROL: **Aurobindo Pharma Q2: Net profit rises 32.5% to Rs 1,124 crore, revenue hits record high** — Aurobindo Pharma reported a 32.5% rise in net profit to Rs 1,124 crore for the second quarter, while its revenue reached a record high. The company's financial performance for the period was highlighted in recent earnings updates. — [Source](https://www.moneycontrol.com/news/business/earnings/aurobindo-pharma-q2-net-profit-rises-32-5-to-rs-1-124-crore-revenue-hits-record-high-14070340.html)
- 2026-11-02 — BUSINESSTODAY: **Diwali picks: HAL, Kotak Bank, TechM, Sona BLW, Auro Pharma among top picks for upto 50% upside** — Axis Securities presented technical stock picks for the year ahead, assigning buy ratings with specific target prices to multiple listed companies including Aurobindo Pharma Ltd, Hindustan Aeronautics Ltd, IOL Chemicals and Pharmaceuticals Ltd, Jyoti CNC Automation Ltd, Kotak Mahindra Bank Ltd, Karnataka Bank Ltd, Dr Lalpath Labs Ltd, Mayur Uniquoters Ltd, Shivalik Bimetal Controls Ltd, and Sona BLW Precision Forgings Ltd. The analysis also identified Tech Mahindra Ltd and Welspun Living Ltd as having positive momentum structures suggesting upside potential. — [Source](https://www.businesstoday.in/markets/stocks/story/diwali-picks-hal-kotak-bank-techm-sona-blw-auro-pharma-among-top-picks-for-upto-50-upside-565067-2026-11-02)
- 2026-11-01 — Mint: **Cash rewards coming? PFC, CONCOR, RITES, to Sonata- These firms to announce dividend with Q2 results 2026 this week** — Multiple companies including Power Finance Corporation, Container Corporation of India Limited, RITES, and Sonata Software are scheduled to hold board meetings this week to announce Q2FY27 results and potentially approve dividends. — [Source](https://www.livemint.com/market/stock-market-news/cash-rewards-coming-pfc-concor-rites-pfc-to-sonata-these-firms-to-announce-dividend-with-q2-results-2026-this-week-11793537407103.html)
- 2026-10-30 — BUSINESSTODAY: **HAL, Kotak Bank, Tech Mahindra, Sona BLW Precision: Top Diwali 2026 Picks by Axis Securities** — Axis Securities issued Diwali 2026 technical buy recommendations for multiple Indian equities, citing breakout patterns and momentum indicators as drivers for potential upside. The broker identified specific support zones and target price ranges for stocks including Aurobindo Pharma, HAL, IOL Chemicals, Jyoti CNC Automation, Kotak Mahindra Bank, Karnataka Bank Limited, Dr. Lal Path Labs, Mayur Uniquoters, Shivalik Bimetal Controls, Welspun Living, Sona BLW Precision Forgings Limited, and Tech Mahindra. — [Source](https://www.businesstoday.in/markets/stocks/story/hal-kotak-bank-tech-mahindra-sona-blw-precision-top-diwali-2026-picks-by-axis-securities-564808-2026-10-30)
- 2026-10-20 — BUSINESSTODAY: **Sona BLW, Solar Industries, Oracle, Aurobindo Pharma, CG Power: Midcap performers of 2026, price targets and more** — Sona BLW, Solar Industries, Oracle, Aurobindo Pharma, CG Power: Midcap performers of 2026, price targets — [Source](https://www.businesstoday.in/markets/stocks/story/sona-blw-solar-industries-oracle-aurobindo-pharma-cg-power-midcap-performers-of-2026-price-targets-and-more-562627-2026-10-20)
- 2026-10-19 — Economic Times: **Pharma Q2 Outlook: Pricing pressure, US competition to weigh on select players** — India's pharmaceutical companies are expected to have a mixed performance in the upcoming September quarter. Companies like Sun Pharmaceutical Industries and Aurobindo Pharma are likely to report good growth. In contrast, Dr Reddy's Laboratories and Lupin may face challenges due to increased competition and a high base. Pricing pressure and elevated raw material costs are also expected to impact overall performance. — [Source](https://economictimes.indiatimes.com/markets/stocks/earnings/indias-pharmaceutical-companies-to-report-mixed-results-as-domestic-growth-offsets-pricing-pressures/articleshow/135037267.cms)
- 2026-10-05 — BUSINESSTODAY: **Holding pharma stocks? Minor correction offers buying opportunity, says analyst** — pharma stocks, Indian pharma sector, Kranti Batini, Edelweiss Securities, pharma rally, healthcare stocks, hospital stocks, buy pharma on dips, term investment, long term investment, Cipla news, Sun Pharma update, Piramal Pharma news, Aurobindo Pharma news, Indian stock market sectors, defensive sectors India, pharma market outlook, healthcare sector outlook, stock market correction, sectoral investment strategy — [Source](https://www.businesstoday.in/markets/stocks/story/holding-pharma-stocks-minor-correction-is-a-buying-opportunity-says-bathini-559556-2026-10-05)
- 2026-10-01 — FREEPRESSJOURNAL.IN: **Aurobindo Pharma Enters US Dermatology Market With Launch Of ADQUEY Ointment For Atopic Dermatitis** — Hyderabad-based Aurobindo Pharma has launched ADQUEY ointment in the US through its subsidiary Acrotech Biopharma, marking its entry into the American dermatology market. The non-steroidal treatment targets mild-to-moderate atopic dermatitis in patients aged two and above — [Source](https://www.freepressjournal.in/business/aurobindo-pharma-enters-us-dermatology-market-with-launch-of-adquey-ointment-for-atopic-dermatitis)
- 2026-10-01 — The Hindu: **SEBI clears corporate bond index futures for NSE** — SEBI clears NSE’s corporate bond index futures to hedge bond exposure, pending RBI approval, boosting derivatives and market liquidity. — [Source](https://www.thehindubusinessline.com/markets/sebi-clears-corporate-bond-index-futures-for-nse/article71531326.ece)
- 2026-10-01 — BUSINESSTODAY: **GIFT Nifty down 110 points; NSE, YES Bank, TechM, Moneyview, Auro Pharma among top stocks in focus** — GIFT Nifty down 110 points; NSE, YES Bank, TechM, Moneyview, Auro Pharma among top stocks in focus — [Source](https://www.businesstoday.in/markets/stocks/story/gift-nifty-down-110-points-nse-yes-bank-techm-moneyview-auro-pharma-among-top-stocks-in-focus-558932-2026-10-01)
- 2026-10-01 — The Hindu: **Markets head for negative open as FII outflows outweigh oil relief** — GIFT Nifty futures were at 22,570 as of 7:38 a.m. IST, signaling a negative start for the Nifty 50, which closed at 22,620.45 on Wednesday — [Source](https://www.thehindubusinessline.com/markets/markets-head-for-negative-open-as-fii-outflows-outweigh-oil-relief/article71531256.ece)
- 2026-10-01 — The Hindu: **These stocks will see heightened activity on October 1** — Stocks across autos, tech, and infrastructure set for mixed moves — [Source](https://www.thehindubusinessline.com/markets/these-stocks-will-see-heightened-activity-on-october-1/article71531230.ece)
- 2026-10-01 — The Hindu: **Aurobindo’s arm, Acrotech Biopharma, launches Adquey in US** — Acrotech Biopharma launches Adquey in the U.S., expanding into dermatology with a dedicated platform and new market opportunities. — [Source](https://www.thehindubusinessline.com/companies/aurobindos-arm-acrotech-biopharma-launches-adquey-in-us/article71531190.ece)
- 2026-09-30 — CNBC-TV18: **Aurobindo Pharma arm Acrotech Biopharma launches ADQUEY in US dermatology market** — Shares of Aurobindo Pharma Ltd ended at ₹1,666.50, down by ₹36.50, or 2.14%, on the BSE. — [Source](https://www.cnbctv18.com/market/stocks/aurobindo-pharma-share-price-arm-acrotech-biopharma-launches-adquey-in-us-dermatology-market-20002488.htm)
- 2026-09-30 — MONEYCONTROL: **Aurobindo Pharma gets Rs 4.60-crore GST setback as appellate authority upholds ITC demand** — Aurobindo Pharma GST, Aurobindo Pharma share price, Aurobindo Pharma GST demand, Aurobindo Pharma ITC, Aurobindo Pharma latest news, GST appellate tribunal, excess input tax credit, Aurobindo Pharma regulatory filing, Telangana GST order, Aurobindo Pharma stock — [Source](https://www.moneycontrol.com/news/business/aurobindo-pharma-gets-rs-4-60-crore-gst-setback-as-appellate-authority-upholds-itc-demand-14041631.html)
- 2026-09-30 — The Hindu: **IPO Listing Live: Adroit Industries (India), Elevate Campuses, Swastika Infra, Armee Infotech shares list on NSE, BSE today** — Adroit Industries (India), Elevate Campuses, Swastika Infra, Armee Infotech listing & share price live updates: businessline is bringing you real-time market data, keeping you updated with the latest market movements as they happen. — [Source](https://www.thehindubusinessline.com/markets/armee-infotech-swastika-infra-elevate-campuses-ipo-listing-and-share-live-news-updates-sep-30/article71526737.ece)
- 2026-09-30 — The Hindu: **GST appellate authority upholds ₹4.6 crore ITC claim order against Aurobindo Pharma** — Telangana GST appellate authority upholds ₹4.6 crore ITC reversal against Aurobindo Pharma; plans appeal, no material impact on operations. — [Source](https://www.thehindubusinessline.com/companies/gst-appellate-authority-upholds-46-crore-itc-claim-order-against-aurobindo-pharma/article71526562.ece)
- 2026-09-25 — Mint: **Indian stock market slides, but 28 Nifty 500 stocks hit fresh 1-year highs this week; MCX, PVR Inox among them** — The Nifty 50 index experienced its biggest decline since 2020, down 0.88% over the last week. Despite a wider market sell-off, stocks like Welspun Corp and Zydus Lifesciences reached new peaks, highlighting selective investor interest amid high crude oil prices and global bond yield fluctuations. — [Source](https://www.livemint.com/market/stock-market-news/indian-stock-market-slides-but-28-nifty-500-stocks-hit-fresh-1-year-highs-this-week-mcx-pvr-inox-among-them-11790344289040.html)
- 2026-09-21 — Economic Times: **Nifty outlook: Can the index defend the crucial 23,000 level?** — The Nifty index has extended its losing streak, testing key support levels. Recent recovery indicates demand, but the broader trend remains under pressure. Experts suggest specific options strategies and stock picks for the week. Several stocks like Sona Com, Auro Pharma, and PhysicsWallah are recommended for buying. Trading strategies focus on potential bounces and retracements in the market. — [Source](https://economictimes.indiatimes.com/markets/stocks/news/nifty-hovers-near-23000-floor-as-analysts-predict-uncertain-market-trends-ahead/articleshow/134377996.cms)
- 2026-09-21 — MONEYCONTROL: **Moneycontrol Pro Market Outlook | Markets brace for fresh volatility amid oil swings and Fed tightening** — markets, MARKET OUTLOOK, opinion — [Source](https://www.moneycontrol.com/news/opinion/moneycontrol-pro-market-outlook-markets-brace-for-fresh-volatility-amid-oil-swings-and-fed-tightening-14033832.html)

## Business profile

**Strategic vision:** Develops, manufactures, and commercializes generic pharmaceuticals and APIs.

### Business segments
- **North America (APUSA):** Aurobindo Pharma USA Inc (APUSA) is the sales and marketing arm in the US, distributing oral solid dosages and other products through various subsidiaries.
- **Europe:** Aurobindo Pharma operates a full-fledged sales infrastructure in 10 European countries, offering a product portfolio covering various therapeutic segments.
- **Specialty Products (Eugia Pharma Specialities Ltd.):** Eugia Pharma Specialities Ltd. is a subsidiary specializing in general injectables and oncology products, operating globally with multiple manufacturing facilities.
- **Research and Development:** Aurobindo Pharma has a strong R&D focus with 9 centers dedicated to enhancing patient impact through continuous research.

### Competitive strengths
- Global regulatory approvals for manufacturing facilities
- In-house API manufacturing capabilities
- Extensive global commercial infrastructure

## Related stocks

- [Abbott India Limited (Healthcare)](https://faxioms.com/stocks/abbotindia) — -0.85%
- [Alkem Laboratories Limited (Healthcare)](https://faxioms.com/stocks/alkem) — +2.06%
- [Biocon Limited (Healthcare)](https://faxioms.com/stocks/biocon) — +0.86%
- [Cipla Limited (Healthcare)](https://faxioms.com/stocks/cipla) — +0.49%
- [Dr. Reddy's Laboratories Limited (Healthcare)](https://faxioms.com/stocks/drreddy) — +0.51%

## Freshness and sources

- Data as of: 2026-11-06
- Source: Faxioms public stock analysis API

Canonical: https://faxioms.com/stocks/auropharma
Markdown representation: https://faxioms.com/stocks/auropharma?render=md